KR101716215B1 - 즉시 주입가능한 젬시타빈 용액 - Google Patents

즉시 주입가능한 젬시타빈 용액 Download PDF

Info

Publication number
KR101716215B1
KR101716215B1 KR1020147029928A KR20147029928A KR101716215B1 KR 101716215 B1 KR101716215 B1 KR 101716215B1 KR 1020147029928 A KR1020147029928 A KR 1020147029928A KR 20147029928 A KR20147029928 A KR 20147029928A KR 101716215 B1 KR101716215 B1 KR 101716215B1
Authority
KR
South Korea
Prior art keywords
solution
gemcitabine
injection
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
KR1020147029928A
Other languages
English (en)
Korean (ko)
Other versions
KR20150014438A (ko
Inventor
사마르트 쿠마르
프라샨트 케인
알로크 비 남데오
수브하스 비 보우믹
키르티 가노르카르
Original Assignee
썬 파마슈티컬 인더스트리스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48325397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101716215(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 썬 파마슈티컬 인더스트리스 리미티드 filed Critical 썬 파마슈티컬 인더스트리스 리미티드
Publication of KR20150014438A publication Critical patent/KR20150014438A/ko
Application granted granted Critical
Publication of KR101716215B1 publication Critical patent/KR101716215B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
    • B65D85/42—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure for ampoules; for lamp bulbs; for electronic valves or tubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020147029928A 2012-04-27 2013-04-26 즉시 주입가능한 젬시타빈 용액 KR101716215B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1334MU2012 2012-04-27
IN1334/MUM/2012 2012-04-27
PCT/IN2013/000281 WO2013171763A1 (en) 2012-04-27 2013-04-26 Ready to be infused gemcitabine solution

Publications (2)

Publication Number Publication Date
KR20150014438A KR20150014438A (ko) 2015-02-06
KR101716215B1 true KR101716215B1 (ko) 2017-03-27

Family

ID=48325397

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029928A KR101716215B1 (ko) 2012-04-27 2013-04-26 즉시 주입가능한 젬시타빈 용액

Country Status (16)

Country Link
US (1) US9241948B2 (zh)
EP (1) EP2656848B2 (zh)
JP (1) JP6159567B2 (zh)
KR (1) KR101716215B1 (zh)
CN (3) CN109077995A (zh)
AU (1) AU2013261012B2 (zh)
BR (1) BR112014026334B1 (zh)
CA (1) CA2871061C (zh)
ES (1) ES2537294T5 (zh)
MX (1) MX357935B (zh)
PL (1) PL2656848T5 (zh)
PT (1) PT2656848E (zh)
RU (1) RU2621144C2 (zh)
SI (1) SI2656848T2 (zh)
WO (1) WO2013171763A1 (zh)
ZA (1) ZA201408502B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9064577B2 (en) 2012-12-06 2015-06-23 Micron Technology, Inc. Apparatuses and methods to control body potential in memory operations
JP2015000869A (ja) * 2013-06-18 2015-01-05 サムヤン バイオファーマシューティカルズ コーポレイション 有機溶媒無含有ゲムシタビン水溶液組成物
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
JP6033931B2 (ja) * 2015-07-30 2016-11-30 サムヤン バイオファーマシューティカルズ コーポレイション 有機溶媒無含有ゲムシタビン水溶液組成物
US10114999B1 (en) 2016-12-02 2018-10-30 Koupon Media, Inc. Using dynamic occlusion to protect against capturing barcodes for fraudulent use on mobile devices
AU2019355057A1 (en) * 2018-10-04 2021-05-27 Daniel E. Levy Method for preparing and delivering bisantrene formulations
WO2021028842A1 (en) * 2019-08-13 2021-02-18 Hetero Healthcare Limited A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same
KR20240084203A (ko) * 2022-12-06 2024-06-13 주식회사 삼양홀딩스 안정성이 향상된 상온 보관용 젬시타빈 수용액제 및 그 제조 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089329A1 (en) 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US20060154891A1 (en) * 2004-12-23 2006-07-13 Edgar Schridde Ready-to-use gemcitabine solutions and gemcitabin concentrates
CN101428035A (zh) 2007-12-11 2009-05-13 常州安孚立德药业技术有限公司 一种盐酸吉西他滨或吉西他滨组合物
JP2012017308A (ja) 2010-07-09 2012-01-26 Nipro Corp ゲムシタビン水溶液製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135498A (en) * 1990-04-02 1992-08-04 Kam Robert J Controlled release infusion device
US20050031679A1 (en) * 1998-03-27 2005-02-10 Clemens Unger Method for producing liposomal formulations of active ingredients
US7267885B1 (en) * 2000-03-16 2007-09-11 Baxter International Inc. Containers and peelable seal containers of new non-PVC material
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
DE10323279A1 (de) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabin-Lösungen
US20060046964A1 (en) * 2004-09-02 2006-03-02 Andre Morneau Pharmaceutical formulations and methods
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
CN101088492B (zh) * 2006-06-12 2012-02-22 齐鲁制药(海南)有限公司 盐酸吉西他滨稳定的过饱和溶液及其制备方法
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
EP2262493B1 (en) * 2008-03-07 2015-02-25 Topotarget A/S Methods of treatment employing prolonged continuous infusion of belinostat
WO2011000811A2 (en) † 2009-06-30 2011-01-06 Novartis Ag Organic compounds
JP5563528B2 (ja) * 2010-06-29 2014-07-30 高田製薬株式会社 ニコチン酸アミドを含有するゲムシタビン凍結乾燥製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089329A1 (en) 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US20060154891A1 (en) * 2004-12-23 2006-07-13 Edgar Schridde Ready-to-use gemcitabine solutions and gemcitabin concentrates
CN101428035A (zh) 2007-12-11 2009-05-13 常州安孚立德药业技术有限公司 一种盐酸吉西他滨或吉西他滨组合物
JP2012017308A (ja) 2010-07-09 2012-01-26 Nipro Corp ゲムシタビン水溶液製剤

Also Published As

Publication number Publication date
WO2013171763A1 (en) 2013-11-21
MX2014013101A (es) 2015-01-26
AU2013261012B2 (en) 2017-02-02
US20130288994A1 (en) 2013-10-31
AU2013261012A1 (en) 2014-11-13
MX357935B (es) 2018-07-31
KR20150014438A (ko) 2015-02-06
BR112014026334B1 (pt) 2022-04-12
BR112014026334A8 (pt) 2021-06-15
JP2013231029A (ja) 2013-11-14
EP2656848B2 (en) 2018-09-19
ES2537294T3 (es) 2015-06-05
CA2871061C (en) 2017-06-20
PL2656848T3 (pl) 2015-10-30
SI2656848T1 (sl) 2015-07-31
ES2537294T5 (es) 2018-12-10
SI2656848T2 (sl) 2019-04-30
EP2656848A1 (en) 2013-10-30
ZA201408502B (en) 2015-11-25
JP6159567B2 (ja) 2017-07-05
BR112014026334A2 (pt) 2017-06-27
US9241948B2 (en) 2016-01-26
PL2656848T5 (pl) 2019-02-28
EP2656848B1 (en) 2015-04-08
CA2871061A1 (en) 2013-11-21
PT2656848E (pt) 2015-07-01
RU2014147388A (ru) 2016-06-20
CN104254319A (zh) 2014-12-31
RU2621144C2 (ru) 2017-05-31
CN113577019A (zh) 2021-11-02
CN109077995A (zh) 2018-12-25

Similar Documents

Publication Publication Date Title
KR101716215B1 (ko) 즉시 주입가능한 젬시타빈 용액
JP7029510B2 (ja) 灌流投与剤形
KR100889090B1 (ko) 에스몰올 제제
KR102374500B1 (ko) 바이오프테린 유도체를 포함하는 고체 약제학적 조성물 및 이러한 조성물의 용도
AU2002309475B2 (en) Esmolol formulation
JP2019511573A (ja) 非経口投与用ホスホマイシン製剤
AU2017376960A1 (en) Micafungin compositions
US20220000776A1 (en) Parenteral dosage form of amiodarone
WO2019213268A1 (en) Ready-to-use liquid parenteral formulations of ribavirin
WO2024100679A1 (en) Parenteral formulations of flucytosine
EP3943068A1 (en) Suxamethonium composition and prefilled syringe thereof
MR et al. A Comprehensive Review on Parenterals
EP4226926A1 (en) Stable ready-to-dilute pharmaceutical formulation comprising cyclophosphamide
Venturella et al. Monitoring and use of antimycotic (micafungin) for systemic use provided by the pharmacy of Marsala Hospital, Italy

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20200226

Year of fee payment: 4